950769-60-5

Basic information

• Product Name: 7-[2-(4-Morpholinyl)ethoxy]-2-(4-nitrophenyl)imidazo[2,1-b]benzothiazole
• Synonyms: 4-[2-[2-(4-nitrophenyl)imidazo[2,1-b][1,3]benzothiazol-6-yl]oxyethyl]morpholine;Imidazo[2,1-b]benzothiazole, 7-[2-(4-morpholinyl)ethoxy]-2-(4-nitrophenyl)-;7-[2-(4-Morpholinyl)ethoxy]-2-(4-nitrophenyl)imidazo[2,1-b]benzothiazole
• CAS NO: 950769-60-5
• Molecular Formula: C₂₁H₂₀N₄O₄S
• Molecular Weight: 424.4729
• Mol File: 950769-60-5.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Density: 1.479g/cm³
• Refractive Index: 1.724
• CAS DataBase Reference: 7-[2-(4-Morpholinyl)ethoxy]-2-(4-nitrophenyl)imidazo[2,1-b]benzothiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 7-[2-(4-Morpholinyl)ethoxy]-2-(4-nitrophenyl)imidazo[2,1-b]benzothiazole(950769-60-5)
• EPA Substance Registry System: 7-[2-(4-Morpholinyl)ethoxy]-2-(4-nitrophenyl)imidazo[2,1-b]benzothiazole(950769-60-5)

Safety Data

• Hazardous Substances Data: 950769-60-5(Hazardous Substances Data)

Usage

General Description

7-[2-(4-Morpholinyl)ethoxy]-2-(4-nitrophenyl)imidazo[2,1-b]benzothiazole, also known as GNE-493, is a chemical compound that belongs to the class of benzothiazole derivatives. It is a potent and selective inhibitor of the checkpoint kinase 1 (Chk1), which is an important protein involved in the regulation of the cell cycle and DNA repair. GNE-493 has shown promising anti-cancer activity in preclinical studies, and it is being investigated as a potential treatment for a variety of cancers, including lung, breast, and colon cancer. Its ability to selectively target Chk1 makes it a promising candidate for combination therapies with other anti-cancer drugs. GNE-493 has the potential to improve the treatment options for cancer patients and may contribute to the development of more effective and personalized cancer therapies.

InChI:InChI=1/C21H20N4O4S/c26-25(27)16-3-1-15(2-4-16)18-14-24-19-6-5-17(13-20(19)30-21(24)22-18)29-12-9-23-7-10-28-11-8-23/h1-6,13-14H,7-12H2

Upstream product

• 3240-94-6 N-(2-chlorethyl)morpholine 
• 914224-34-3 2-(4-nitrophenyl)imidazo[2,1-b][1,3]benzothiazol-7-ol 
• 3647-69-6 4-(2-chloroethyl)morpholine hydrochride 
• 99-81-0 4-Nitrophenacyl bromide 
• 26278-79-5 2-amino-6-hydroxybenzothiazole 
• 1747-60-0 6-methoxybenzothiazol-2-ylamine 
• 100-02-7 4-nitro-phenol 
• 65300-53-0 4-[2-(4-nitrophenoxy)ethyl]morpholine 
• 52481-41-1 4-(2-morpholinoethoxy)aniline 

Downstream Products

• 950769-58-1 quizartinib 
• 1132827-21-4 Quizartinib dihydrochloride 
• 950769-61-6 2-(4-aminophenyl)-7-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazole 

Relevant articles and documents

Benzo imidazo [2, 1-b] thiazole compound and application thereof (by machine translation)

The invention discloses a benzoimidazo [2, 1-b] thiazole compound and application thereof, and belongs to the technical field of medicines. The inhibitory activity of the synthesized benzimidazo [2, 1-b] thiazole analogues on FLTT3 is more than 90%, wherein the compounds (compounds 2 , 4, 6, 8 and 10) are IC of FLTT3-ITD kinase. 50 Lower value, in particular compound 2, IC IC50 The value is only 5.60 nm, and therefore the compound of the present invention may be used as an inhibitor FLTT3, or for preparing a drug capable of modulating or suppressing diseases associated with abnormal cell proliferation by affecting the enzymatic activity of one or more tyrosine kinases and interfering with aberrant cell proliferation, having a wide application prospect. (by machine translation)

PROCESS FOR THE PREPARATION OF IMIDAZO[2,1-B][1,3]BENZOTHIAZOLE DERIVATIVES

Provided herein are process for the preparation of N-(5-ferf-butyl-isoxazol-3-yl)- N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,l-fe][l,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt, solvate, hydrate, or polymorph thereof. N-(5-tert- Butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,l-and][l,3]benzo- thiazol-2-yl]phenyl}urea is useful for treating, preventing, and/or managing diseases or conditions, including but not limited to, proliferative diseases, FLT-3 mediated diseases, and cancers. N-(5-ferf-Butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl- ethoxy)imidazo[2,l-and][l,3]benzothiazol-2-yl]phenyl}urea is represented by the structure:

IMIDAZOLOTHIAZOLE COMPOUNDS AS MODULATORS OF PROTEIN KINASE

Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.